<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803918</url>
  </required_header>
  <id_info>
    <org_study_id>TDR14311</org_study_id>
    <secondary_id>U1111-1176-6142</secondary_id>
    <nct_id>NCT02803918</nct_id>
  </id_info>
  <brief_title>A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as
      compared to placebo in pediatric patients with T2DM.

      Secondary Objectives:

        -  To evaluate plasma concentrations of lixisenatide after repeated doses (3 ascending
           doses) and pharmacokinetic parameters of repeated lixisenatide doses in pediatric
           patients with T2DM.

        -  To evaluate the change from baseline in fasting and post-prandial plasma glucose
           concentrations during a standardized meal test after 3 ascending repeated doses of
           lixisenatide in comparison to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration will be up to 10 weeks that includes a 6-week treatment period with
      dose escalation every 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">January 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events (AEs)</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with anti-lixisenatide antibodies</measure>
    <time_frame>Up to 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic (PK) parameters: lixisenatide plasma concentration</measure>
    <time_frame>Day 14, Day 28 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters: maximum concentration (Cmax)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters: time to reach Cmax (Tmax)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters: area under up to last concentration (AUClast)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameters: area under curve (AUC)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours</measure>
    <time_frame>Day 14, Day 28 and Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide (AVE0010)</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Lixisenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal Insulin</intervention_name>
    <description>Pharmaceutical form: solution
Route of administration: subcutaneous</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female patients aged ≥10 and &lt;18 years old (at least 4 patients below 16 years
             old).

          -  Body mass index (BMI) &gt;85th percentile for age and gender; BMI ≤50 kg/m2.

          -  Male and female patients with documented T2DM insufficiently controlled with metformin
             at a stable dose and regimen for 8 weeks prior to randomization and/or basal insulin
             at stable dose (± 20%) and regimen for 8 weeks prior to randomization. The exact
             individual metformin dose will be selected according to local regulation and to the
             investigator's medical judgment.

          -  Glycated hemoglobin (HbA1c) &gt;6.5% and ≤11% at screening.

        Exclusion criteria:

          -  If female, ongoing pregnancy (defined as positive serum pregnancy test),
             breast-feeding.

          -  Sexually active postmenarchal female patient who does not agree to use an adequate and
             highly effective method of contraception throughout the study duration and according
             to local regulation (ie, hormonal contraception, condom, etc.).

          -  Diabetes other than T2DM.

          -  Fasting plasma glucose &gt;250 mg/dL (&gt;13.9 mmol/L) at screening.

          -  Use of other oral or injectable antidiabetic or hypoglycemic agents other than
             metformin and basal insulin (eg, alpha glucosidase inhibitor, glucagon-like peptide
             (GLP-1) receptor agonist, dipeptidyl peptidase-IV (DPP-IV) inhibitors, short-acting
             insulin etc.) within 1 month prior to the screening visit.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115-6969</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 480001</name>
      <address>
        <city>Phoenix</city>
        <country>Mauritius</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Puebla</city>
        <zip>72190</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710-001</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Vitoria</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mauritius</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

